Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2019 00:00 ET | Source: Dermira, Inc.

Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth

New multichannel consumer campaign will feature QBREXZA patientsCampaign to drive consumer awareness of QBREXZAQBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment...
March 22, 2019 16:01 ET | Source: Dermira, Inc.

Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
March 19, 2019 19:36 ET | Source: Dermira, Inc.

Dermira Prices $130.0 Million Public Offering of Common Stock

MENLO PARK, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
March 18, 2019 16:30 ET | Source: Dermira, Inc.

Dermira Announces Proposed Public Offering of Common Stock

MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
March 18, 2019 07:00 ET | Source: Dermira, Inc.

Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

- All three doses of lebrikizumab met primary endpoint with statistical significance- Lebrikizumab was well-tolerated; safety profile consistent with prior studies- Efficacy and safety profile support...
March 05, 2019 16:00 ET | Source: Dermira, Inc.

Dermira to Present at the Cowen and Company 39th Annual Health Care Conference

MENLO PARK, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
March 01, 2019 08:00 ET | Source: Dermira, Inc.

Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis

Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary hyperhidrosis New analysis from...
February 26, 2019 16:01 ET | Source: Dermira, Inc.

Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 millionOver 14,500 prescriptions for QBREXZA written in first three months of launchSecured QBREXZA coverage for approximately 76% of...
February 26, 2019 08:00 ET | Source: Dermira, Inc.

Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting

MENLO PARK, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
February 22, 2019 08:00 ET | Source: Dermira, Inc.

Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis

- Study will assess the impact of QBREXZA treatment on sweat severity in patients with primary palmar hyperhidrosis- Results will inform potential development plans for QBREXZA in primary palmar...

Next Page keyboard_arrow_right